{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:10:51Z","timestamp":1785769851356,"version":"3.56.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:p>\n                    Anifrolumab is a type I interferon receptor antagonist approved for the treatment of moderate-to-severe systemic lupus erythematosus. While its efficacy has been demonstrated in clinical trials, its long-term safety remains understudied in the real world. This study extracted relevant data from the FDA Adverse Event Reporting System (FAERS) to evaluate the post-marketing safety profile of anifrolumab in real-world clinical practice and to identify potential safety signals. We analyzed 1293 reports involving 3542 adverse events (AEs) from the FAERS database (Q3 2021\u2013Q1 2025) using disproportionality analysis. Reports in which anifrolumab was designated as the \u201cprimary suspect\u201d drug were included. Safety signals were identified using the reporting odds ratio and the Bayesian confidence propagation neural network, with a signal defined as positive only if it met both criteria: a lower limit of the reporting odds ratio\u2019s 95% confidence interval\u2005&gt;\u20051 and the 95% lower credibility interval for the information component of the Bayesian confidence propagation neural network\u2005&gt;\u20050. Additionally, multivariable logistic regression analyses were performed for key AEs to rule out potential confounding. The study identified 97 positive safety signals associated with anifrolumab. In addition to the labeled AEs, such as infusion-related reactions and infections, several unexpected AEs were also identified, including renal-related, cardiovascular-related, and neurological AEs. Multivariable logistic regression analyses for key AEs showed that concomitant immunosuppressants, comorbidities, and disease severity were not significant independent predictors (all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05), supporting the robustness of the identified signals. This pharmacovigilance study provides hypothesis-generating evidence on the post-marketing safety profile of anifrolumab and highlights several potential safety signals that warrant further evaluation. It is crucial to emphasize that these findings are derived from the FAERS, a spontaneous reporting database that cannot establish causality due to inherent limitations, such as underreporting, missing data, and lack of exposure information. Therefore, these results require confirmation in well-designed observational studies and clinical trials. Clinicians should be aware of these potential associations and consider appropriate monitoring.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048274","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:00:25Z","timestamp":1775840425000},"page":"e48274","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety profile of anifrolumab: An observational disproportionality analysis of the FAERS database"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4993-8887","authenticated-orcid":false,"given":"Qi","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Third People\u2019s Hospital of Hangzhou, Hangzhou, Zhejiang, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Third People\u2019s Hospital of Hangzhou, Hangzhou, Zhejiang, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260410","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R2-20260410","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus.","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"R3-20260410","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study.","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R4-20260410","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/0022034518760855","article-title":"Activation of stimulator of interferon genes (STING) and Sj\u00f6gren syndrome.","volume":"97","author":"Papinska","year":"2018","journal-title":"J Dent Res"},{"key":"R5-20260410","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis.","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"R6-20260410","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"R7-20260410","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus.","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"R8-20260410","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14740338.2023.2284989","article-title":"Newly identified adverse events for gemcitabine using the food and drug administration adverse event reporting system.","volume":"23","author":"Zhang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R9-20260410","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associateddrug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis.","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"R10-20260410","doi-asserted-by":"crossref","first-page":"e0328371","DOI":"10.1371\/journal.pone.0328371","article-title":"Update of safety profile of bile acid sequestrants: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System.","volume":"20","author":"Chen","year":"2025","journal-title":"PLoS One"},{"key":"R11-20260410","doi-asserted-by":"crossref","first-page":"1226086","DOI":"10.3389\/fphar.2023.1226086","article-title":"Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA Adverse Event Reporting System.","volume":"14","author":"Xiong","year":"2023","journal-title":"Front Pharmacol"},{"key":"R12-20260410","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The Medical Dictionary for Regulatory Activities (MedDRA).","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"R13-20260410","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"Von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"R14-20260410","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R15-20260410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013non-case studies: principle.","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapies"},{"key":"R16-20260410","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures.","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R17-20260410","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies.","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20260410","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1093\/rheumatology\/kead568","article-title":"Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.","volume":"63","author":"Miyazaki","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20260410","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3899\/jrheum.2024-0053","article-title":"Anifrolumab in refractory systemic lupus erythematosus: a real-world, multicenter study.","volume":"51","author":"Tani","year":"2024","journal-title":"J Rheumatol"},{"key":"R20-20260410","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2881","article-title":"Overview of the biology of type I interferons.","volume":"12","author":"Kalliolias","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R21-20260410","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s12519-024-00811-4","article-title":"Type I interferon pathway in pediatric systemic lupus erythematosus.","volume":"20","author":"Zhou","year":"2024","journal-title":"World J Pediatr"},{"key":"R22-20260410","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12879-020-05730-z","article-title":"JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis.","volume":"21","author":"Walz","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R23-20260410","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus.","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R24-20260410","doi-asserted-by":"crossref","first-page":"e005076","DOI":"10.1136\/rmdopen-2024-005076","article-title":"Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab.","volume":"11","author":"Trefond","year":"2025","journal-title":"RMD Open"},{"key":"R25-20260410","doi-asserted-by":"crossref","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"key":"R26-20260410","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40521-020-00242-2","article-title":"Hypersensitivity reactions to biologicals: from bench to bedside.","volume":"7","author":"Akarsu","year":"2020","journal-title":"Curr Treat Options Allergy"},{"key":"R27-20260410","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00393-018-0541-3","article-title":"Pathogenese des systemischen lupus erythematodes.","volume":"77","author":"Finzel","year":"2018","journal-title":"Z F\u00fcr Rheumatol"},{"key":"R28-20260410","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.cyto.2011.08.026","article-title":"The role of tumor necrosis factor-alpha (TNF-\u03b1) in the pathogenesis of systemic lupus erythematosus.","volume":"56","author":"Postal","year":"2011","journal-title":"Cytokine"},{"key":"R29-20260410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/09612033251317783","article-title":"Investigating the role of IL-6 in the pathogenesis of systemic lupus erythematosus: insights from bone marrow mesenchymal stem cells.","volume":"34","author":"Zhang","year":"2025","journal-title":"Lupus"},{"key":"R30-20260410","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.24499","article-title":"Th17 and natural Treg cell population dynamics in systemic lupus erythematosus.","volume":"60","author":"Yang","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R31-20260410","doi-asserted-by":"crossref","first-page":"1489205","DOI":"10.3389\/fimmu.2024.1489205","article-title":"Therapeutically targeting proinflammatory type I interferons in systemic lupus erythematosus: efficacy and insufficiency with a specific focus on lupus nephritis.","volume":"15","author":"Lai","year":"2024","journal-title":"Front Immunol"},{"key":"R32-20260410","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R33-20260410","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R34-20260410","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5664\/jcsm.11014","article-title":"Brain fog in central disorders of hypersomnolence: a review.","volume":"20","author":"Rosenberg","year":"2024","journal-title":"J Clin Sleep Med"},{"key":"R35-20260410","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40744-021-00312-0","article-title":"Cognitive dysfunction in systemic lupus erythematosus: immunopathology, clinical manifestations, neuroimaging and management.","volume":"8","author":"Seet","year":"2021","journal-title":"Rheumatol Ther"},{"key":"R36-20260410","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/art.40933","article-title":"Cognitive dysfunction in systemic lupus erythematosus: a case for initiating trials.","volume":"71","author":"Kello","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R37-20260410","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00228-025-03849-z","article-title":"Signal detection of ferric carboxymaltose-induced serious adverse events: disproportionality analysis of FAERS and VigiBase data and systematic review of case reports.","volume":"81","author":"Galigutta","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"R38-20260410","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14740338.2024.2392860","article-title":"Ocular adverse events associated with platins: a disproportionality analysis of pharmacovigilance data and extensive systematic review of case reports.","volume":"24","author":"Hasik","year":"2025","journal-title":"Expert Opin Drug Saf"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:22:23Z","timestamp":1785766943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":38,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048274","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2025-09-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}